The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face.
A side effect of the injection of botulinum toxin into the upper third of the face is ptosis or lid droop. A therapy recommended to treat ptosis resulting from administration of botulinum toxins A and B is Iopidine (apraclonidine 0.5 %) eye drops. Apraclonidine is an alpha2-adrenergic agonist, which causes Muller muscles to contract quickly elevating the upper eyelid 1-3 mm. Little published data discusses the use of apraclonidine to treat such ptosis. This communication discusses the extant literature on this usage. Research needs to be done to establish the utility and dosing of apraclonidine for botulinum toxin-induced ptosis.
Scheinfeld
Noah
N
Department of Dermatology, St Luke's Roosevelt Hospital, New York, USA.
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D001763:Blepharoptosis / Q000139:chemically induced / Q000188:drug therapy*; D001905:Botulinum Toxins / Q000009:adverse effects*; D003000:Clonidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D009465:Neuromuscular Agents / Q000009:adverse effects*; D009883:Ophthalmic Solutions
D000316:Adrenergic alpha-Agonists; D009465:Neuromuscular Agents; D009883:Ophthalmic Solutions; C016986:apraclonidine; D001905:Botulinum Toxins; D003000:Clonidine